Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1Suspended 1Not yet recruiting 1Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell 1Lymphoma 1HTLV-I Infections 1

Interventions

Vincristine 2Prednisone 2Doxorubicin 2Cyclophosphamide 2Antibodies, Monoclonal 2sargramostim 1prednylidene 1pembrolizumab 1glucarpidase 1deltacortene 1brincidofovir 1Specimen Handling 1Rituximab 1RFB4(dsFv)-PE38 recombinant immunotoxin 1Methods 1Magnetic Resonance Spectroscopy 1Lenalidomide 1Immunotherapy, Active 1Immunization, Passive 1Health Care Economics and Organizations 1Etoposide 1Drug Therapy 1Coal Tar 1Brentuximab Vedotin 1Biopsy 1Biomarkers 1Biological Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Suspended × Lymphoma × prednylidene × Clear all
NCT04301076 2026-05-13

Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL)

National Cancer Institute (NCI)

Phase 1 Suspended
30 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, HTLV-I Infections, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡